$667 Million is the total value of Omega Fund Management, LLC's 19 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 31.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REPL | Sell | Replimune Group | $193,603,000 | +58.2% | 5,074,783 | -5.1% | 29.03% | -12.3% |
| KRON | New | Kronos Bio | $114,052,000 | – | 3,818,283 | +100.0% | 17.10% | – |
| MORF | Sell | Morphic Holding | $98,025,000 | +20.4% | 2,921,771 | -1.9% | 14.70% | -33.3% |
| SPRB | New | Spruce Biosciences | $52,534,000 | – | 2,161,022 | +100.0% | 7.88% | – |
| AVIR | New | Atea Pharmaceuticals | $35,396,000 | – | 847,208 | +100.0% | 5.31% | – |
| GOSS | Gossamer Bio | $32,110,000 | -22.1% | 3,320,608 | 0.0% | 4.82% | -56.8% | |
| IMUX | Immunic | $27,341,000 | -17.7% | 1,788,160 | 0.0% | 4.10% | -54.4% | |
| CMPI | Checkmate Pharmaceuticals | $19,478,000 | +26.8% | 1,335,050 | 0.0% | 2.92% | -29.7% | |
| ARQT | Sell | Arcutis Biothereapeutics | $18,009,000 | -6.7% | 640,199 | -2.8% | 2.70% | -48.3% |
| SYRS | New | Syros Pharmaceuticals | $16,953,000 | – | 1,562,500 | +100.0% | 2.54% | – |
| PRTK | Paratek Pharmaceuticals | $16,279,000 | +15.7% | 2,600,410 | 0.0% | 2.44% | -35.9% | |
| ALPN | Alpine Immune Sciences | $16,190,000 | +43.4% | 1,284,900 | 0.0% | 2.43% | -20.5% | |
| EPIX | Sell | ESSA Pharma | $8,419,000 | +38.1% | 705,693 | -22.7% | 1.26% | -23.5% |
| FGEN | FibroGen | $4,846,000 | -9.8% | 130,646 | 0.0% | 0.73% | -50.0% | |
| CDTX | Cidara Therapeutics | $4,010,000 | -29.8% | 2,005,249 | 0.0% | 0.60% | -61.1% | |
| TRVI | Sell | Trevi Therapeutics | $3,330,000 | -39.9% | 1,263,408 | -8.2% | 0.50% | -66.7% |
| JNCE | Jounce Therapeutics | $2,345,000 | -14.2% | 334,965 | 0.0% | 0.35% | -52.4% | |
| OBSV | ObsEva | $2,079,000 | -16.1% | 999,364 | 0.0% | 0.31% | -53.4% | |
| PIRS | Pieris Pharmaceuticals | $1,877,000 | +20.8% | 750,741 | 0.0% | 0.28% | -33.1% | |
| PRVL | Exit | Prevail Therapeutics | $0 | – | -187,538 | -100.0% | -0.52% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.